Marion Munk

Company: Isarna THerapeutics
Job title: Chief Medical Officer
Seminars:
Targeting TGF beta 2 mRNA Using Antisense Technology as a New Therapeutic Option in Retinal Diseases 2:00 pm
Targeting TGF beta 2 mRNA using antisense technology as a new therapeutic option in retinal diseases Our lead compound ISTH0036 is a first in class selective second-generation antisense oligonucleotide (ASO) blocking TGF-β2 The phase 1 dose escalation study confirmed the excellent safety profile Currently phase 2 trials are assessing efficacy in wet AMD and DMERead more
day: Day Two